Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
AbbVie Inc (NYSE:ABBV) shares already discount much of the risk emanating from the COVID-19 crisis, according to an analyst at RBC Capital Markets.
The AbbVie Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Randall Stanicky upgraded AbbVie from Sector Perform to Outperform and increased the price target from $79 to $93.
The AbbVie Thesis
Even with the 29% gains since the recent bottom in late March, AbbVie shares are still down 11% since the COVID-19-related downturn that started Feb. 21 compared to a more modest 2% decline by the NYSE Arca Pharmaceutical Index, Stanicky said in a note.
Stanicky expects the company to reaffirm its sector-high 5.7% dividend and provide better clarity on P&L when it issues its quarterly results May 1. EPS guidance for the year could move lower, although a step-up rebound could be in the cards in 2021 against trough valuation.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
"We want to get ahead of that as the market ultimately shifts from defensive to offensive positioning," the analyst wrote in the note.
Related Link: The Week Ahead In Biotech: Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision
Delving on AbbVie's businesses, the analyst sees the COVID-19 impact on the company to be greater than that of peers. Although the consensus has not moved down sufficiently to reflect the risk, the analyst is of the view the focus is quickly shifting to beyond this "transition" year.
Stanicky braces for a messy year for AbbVie, as the Allergan plc (NYSE:AGN) acquisition is expected to close soon and the COVID-19 impact continues into summer. Consequently, the analyst sees some stock disruption.
"But 2021 should "step up" to more "normalized" earnings with relatively quick bounce-back around core franchises," he said.
With the pro forma valuation at historical lows, the firm said the closing of the Allergan deal will serve as a catalyst.
ABBV Price Action
AbbVie shares were up 1.8% to $84.96 at time of publication
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.